Phase 1 Trial of Oral Ixabepilone
Trial ID or NCT#
This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants with advanced cancer
A Phase 1 Study of Ixabepilone Administered as 3 Oral Doses Each Separated by 6 Hours Every 21 Days in Subjects With Advanced Cancer
- - Males and females, 18 or older - Histologically or cytologically confirmed diagnosis of solid tumor malignancy - Measurable or non-measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria - Karnofsky Performance Status (KPS) of 70-100 - Recovered from toxicities resulting from previous therapies
- - More than 3 prior cytotoxic regimens in the metastatic setting - Current or recent gastrointestinal (GI) disease that would impact the absorption of study drug - Inability to swallow whole capsules - Inadequate hepatic and renal function - Function exposure to any epothilone
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office